1. Lipoprotein(a), PCSK9 Inhibition and cardiovascular risk: Insights from the Fourier trial. (August 2018) Authors: O'Donoghue, M.; Giugliano, R.; Keech, A.; Kanevsky, E.; Im, K.; Pineda, A.Lira; Somaratne, R.; Sever, P.; Pederson, T.; Sabatine, M. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗